"The
Report Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz”
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Chemotherapy Induced Neutropenia Pipeline Review, H1
2017, provides an overview of the Chemotherapy Induced Neutropenia
(Oncology) pipeline landscape.
Chemotherapy-induced
neutropenia is a very common side effect of cancer treatment.
Symptoms include severe fatigue, weakness, anxiety, lack of energy,
shortness of breath, headaches, pale appearance, rapid heart rate or
palpitations, chest pain dizziness and abdominal pain. The
predisposing factors include age, co-morbidities and time course of
therapy.
View
Report @ http://www.marketresearchreports.biz/analysis/1021129
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Chemotherapy Induced Neutropenia Pipeline Review, H1 2017, provides
comprehensive information on the therapeutics under development for
Chemotherapy Induced Neutropenia (Oncology), complete with analysis
by stage of development, drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Chemotherapy Induced Neutropenia (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for
Chemotherapy Induced Neutropenia and features dormant and
discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 3, 2, 4, 5, 8, 1, 13, 1
and 1 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 1 molecules, respectively.
Chemotherapy
Induced Neutropenia (Oncology) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built
using data and information sourced from Global Markets Directs
proprietary databases, company/university websites, clinical trial
registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic
tracking processes ensure that the most recent developments are
captured on a real time basis.
Get
Sample Copy Of This Report @
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Chemotherapy Induced Neutropenia (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Chemotherapy
Induced Neutropenia (Oncology) by companies and universities/research
institutes based on information derived from company and
industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
-
The pipeline guide reviews key companies involved in Chemotherapy
Induced Neutropenia (Oncology) therapeutics and enlists all their
major and minor projects.
-
The pipeline guide evaluates Chemotherapy Induced Neutropenia
(Oncology) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued
pipeline projects.
-
The pipeline guide reviews latest news related to pipeline
therapeutics for Chemotherapy Induced Neutropenia (Oncology)
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Chemotherapy Induced Neutropenia (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Chemotherapy Induced Neutropenia (Oncology) pipeline depth and focus
of Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Table
of Contents
List
of Tables
List
of Figures
Introduction
Global
Markets Direct Report Coverage
Chemotherapy
Induced Neutropenia - Overview
Chemotherapy
Induced Neutropenia - Therapeutics Development
Pipeline
Overview
Pipeline
by Companies
Pipeline
by Universities/Institutes
Products
under Development by Companies
Products
under Development by Universities/Institutes
Chemotherapy
Induced Neutropenia - Therapeutics Assessment
Assessment
by Target
Assessment
by Mechanism of Action
Assessment
by Route of Administration
Assessment
by Molecule Type
Chemotherapy
Induced Neutropenia - Companies Involved in Therapeutics Development
Apotex
Inc
Biocon
Ltd
Biogenomics
Ltd
Bolder
Biotechnology Inc
Cellerant
Therapeutics Inc
Chong
Kun Dang Pharmaceutical Corp
Cinfa
Biotech SL
Dr.
Reddy's Laboratories Ltd
Gene
Techno Science Co Ltd
Generon
(Shanghai) Corp Ltd
Genexine
Inc
GlycoMimetics
Inc
Hanmi
Pharmaceuticals Co Ltd
Mycenax
Biotech Inc
Myelo
Therapeutics GmbH
Nohla
Therapeutics Inc
Octapharma
AG
Pfenex
Inc
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment